Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Molitch

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Clinical and Experimental Hypertension (New York, N.Y. : 1993)|February 11, 2005
Diabetes and hypertension: pathogenesis, prevention and treatmentLewis Landsberg, Mark Molitch
Current Opinion in Endocrinology, Diabetes, and Obesity|July 3, 2008
Pituitary stalk lesionsDemetra Rupp, Mark Molitch
Diabetes Care|February 22, 2014
Microalbuminuria as a risk predictor in diabetes: the continuing sagaGeorge L Bakris, Mark Molitch
Diabetes Care|February 22, 2018
Are All Patients With Type 1 Diabetes Destined for Dialysis if They Live Long Enough? Probably NotGeorge L Bakris, Mark Molitch
The Journal of Clinical Endocrinology and Metabolism|April 9, 2011
The Hormone Foundation's Patient guide to pituitary incidentaloma assessment and treatmentPamela Freda, Laurence Katznelson, Mark Molitch
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|February 3, 2012
Delayed anithyroid drug-induced agranulocytosisPriscilla Mutharasan, Wendy Oatis, Hau Kwaan, et al.
Pituitary|January 15, 2013
Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registryRoberto Salvatori, Whitney W Woodmansee, Mark Molitch, et al.
Diabetes, Obesity & Metabolism|June 20, 2008
Risk factor assessment for new onset diabetes: literature reviewGeorge Bakris, Jack Stockert, Mark Molitch, et al.
Life Sciences|February 14, 2012
Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD)Dennis L Andress, Blai Coll, Yili Pritchett, et al.
Journal of the Cardiometabolic Syndrome|March 11, 2008
Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET studyGeorge Bakris, Mark Molitch, Qian Zhou, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Clinical and Experimental Hypertension (New York, N.Y. : 1993)|February 11, 2005
Diabetes and hypertension: pathogenesis, prevention and treatmentLewis Landsberg, Mark Molitch
Current Opinion in Endocrinology, Diabetes, and Obesity|July 3, 2008
Pituitary stalk lesionsDemetra Rupp, Mark Molitch
Diabetes Care|February 22, 2014
Microalbuminuria as a risk predictor in diabetes: the continuing sagaGeorge L Bakris, Mark Molitch
Diabetes Care|February 22, 2018
Are All Patients With Type 1 Diabetes Destined for Dialysis if They Live Long Enough? Probably NotGeorge L Bakris, Mark Molitch
The Journal of Clinical Endocrinology and Metabolism|April 9, 2011
The Hormone Foundation's Patient guide to pituitary incidentaloma assessment and treatmentPamela Freda, Laurence Katznelson, Mark Molitch
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|February 3, 2012
Delayed anithyroid drug-induced agranulocytosisPriscilla Mutharasan, Wendy Oatis, Hau Kwaan, et al.
Pituitary|January 15, 2013
Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registryRoberto Salvatori, Whitney W Woodmansee, Mark Molitch, et al.
Diabetes, Obesity & Metabolism|June 20, 2008
Risk factor assessment for new onset diabetes: literature reviewGeorge Bakris, Jack Stockert, Mark Molitch, et al.
Life Sciences|February 14, 2012
Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD)Dennis L Andress, Blai Coll, Yili Pritchett, et al.
Journal of the Cardiometabolic Syndrome|March 11, 2008
Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET studyGeorge Bakris, Mark Molitch, Qian Zhou, et al.
Pageof 4